RecruitingPhase 3NCT06455449

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Studying Dermatomyositis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Intervention: Anifrolumab (blinded)(combination_product)
Enrollment: 240 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2024 – 2028

Study locations (30)

Research Site, Irvine, California, United States
Research Site, Aurora, Colorado, United States
Research Site, Denver, Colorado, United States
Research Site, New Haven, Connecticut, United States
Research Site, Washington D.C., District of Columbia, United States
Research Site, Boca Raton, Florida, United States
Research Site, Boynton Beach, Florida, United States
Research Site, Gainesville, Florida, United States
Research Site, Margate, Florida, United States
Research Site, Miami, Florida, United States
Research Site, Orlando, Florida, United States
Research Site, Palm Beach Gardens, Florida, United States
Research Site, Plant City, Florida, United States
Research Site, Atlanta, Georgia, United States
Research Site, Willowbrook, Illinois, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06455449 on ClinicalTrials.gov

Other trials for Dermatomyositis

Additional recruiting or active studies for the same condition.

See all trials for Dermatomyositis →

← Back to all trials